Navigation Links
Toward a more efficient therapy for a specific form of leukemia
Date:6/14/2011

Chronic myeloid leukemia (CML) is a particular form of leukemia or cancer of the bone marrow, which can be treated with targeted imatinib. However, in some cases this medicine has no effect. Researchers at the VIB Vesalius Research Centre, K.U. Leuven, under the direction of Peter Carmeliet, have investigated the role of placental growth factor (PlGF) in mice with CML. Blocking this growth factor increases the life expectancy of these mice, even in those resistant to imatinib.

Chronic myeloid leukemia (CML)

In our body, white blood cells combat foreign intruders, such as viruses and bacteria. In chronic myeloid leukemia, the formation of granulocytes, a particular type of white blood cells, is disturbed. The cells in the bone marrow which should grow into white blood cells show an uncontrolled increase in numbers as a result of a disruption in the maturing process. This uncontrolled growth may damage various tissues and adversely affect the production of normal blood cells in the bone marrow. A shortage of white blood cells makes patients more susceptible to infection.

The Philadelphia chromosome and imatinib

Under normal circumstances, our body very accurately regulates the production of white blood cells. This process is triggered by targeted activation of tyrosine kinase. In most forms of CML, a deviant chromosome is present - the Philadelphia chromosome - which gives rise to BCR-ABL1 fusion kinase. This kinase causes the trouble, leading to the increase in CML cells. Existing medicines (imatinib) therefore target this kinase.

While the effect of imatinib in CML patients is usually quite favorable, the use of imatinib is often not sufficient to remove the diseased cells from the body. Sometimes the disease is already too advanced at the start of treatment, or there is resistance.

Placental growth factor

Researchers from the team headed by Peter Carmeliet have studied the role of placental growth factor (PlGF) in leukemia and the therapeutic potential of PIGF inhibitors. Recent research conducted by Peter Carmeliet had already shown that antibodies against PlGF (antiPlGF) can inhibit the growth of particular tumors.

The present study proves that PlGF also plays a role in CML. The researchers have recorded increased PIGF values in both mice and humans. It appears that PIGF does not only stimulate the division of CML cells but also encourages the formation of blood vessels in bone marrow. Finally, inhibiting PlGF in mice with CML leads to higher life expectancy, even in those mice that are resistant to the current medicine imatinib. All of these findings indicate that the therapeutic potential of PIGF inhibitors in CML needs to be investigated further.


'/>"/>

Contact: Evy Vierstraete
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related medicine news :

1. Attitudes toward end-of-life care: A survey of cancer patients and others in Korea
2. NIH grant for the move toward clinical trials targeting the lysosomal storage disease MPSIIIB
3. U.S. Pushes School Cafeterias Toward Healthier Offerings
4. Toward a vaccine for methamphetamine abuse
5. Negative attitudes toward fat bodies going global, study finds
6. Tiny gems take big step toward battling cancer
7. Top scientists unite to develop global scientific strategy Towards An HIV Cure
8. Toward a fast, simple test for detecting cholera rampaging in 40 countries
9. Major step taken toward an open and shared digital brain atlasing framework
10. Warning about benevolent sexism and mens apparently positive attitudes towards women
11. Early Steps Toward an Alzheimers Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Five consumer packaged goods (CPG) products were selected ... different categories. Nopavera Plus was named to the short list in the ... West 2017 during presentations at SupplySide Central on Sept. 27 and 28 at Mandalay ...
(Date:9/20/2017)... , ... September 20, 2017 , ... “The Trials I ... and tribulations as he emotionally pens his aspirations and goals to better one’s life ... published author, Jimmy Green, while searching in all the wrong places, found a love ...
(Date:9/20/2017)... ... ... “Psalms of Humidity”: is a fascinating depiction of daily struggles and the inspirational solutions ... God. “Psalms of Humidity” is the creation of published author, David Waldrop, an imperfect ... are the very same things that have shaped him into the man that he ...
(Date:9/19/2017)... ... September 19, 2017 , ... With a series of fundraising ... than $15,000 in just a couple of weeks for those affected by Hurricane ... instructor seminars, organizers expect to double those initial funds with the “Submit Harvey” ...
(Date:9/19/2017)... BETHESDA, MD (PRWEB) , ... September 19, 2017 ... ... of Environmental Compliance and Safety for the President’s Malaria Initiative (PMI) Africa ... of USAID’s Innovation to Action Award. , The Innovation to Action Award, ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)...   PDI , a leader in infection prevention ... educational session focused on the role of chlorhexidine gluconate ... the 2017 Annual Scientific Meeting of the Association for ... the Phoenix Convention Center in ... will also feature PDI,s Prevantics® Device Swab ...
(Date:9/5/2017)... , Sept. 5, 2017  Getinge, a leading ... a vibrant charitable donation program -- "Color for ... congenital heart defect research by The Children,s Heart ... the general public are encouraged to download a ... the completed artwork to the gallery on the ...
(Date:9/1/2017)... , Sept. 1, 2017  Bayer will present the latest ... Society for Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... include new preclinical and clinical data on Bayer,s marketed portfolio ... pipeline projects. "We ... minds in cancer research at ESMO," said Carsten Brunn ...
Breaking Medicine Technology: